Latest Hansa Biopharma News & Updates

See the latest news and media coverage for Hansa Biopharma. We track all announcements, press releases, and industry mentions in real time, all in one place.

Hansa Biopharma

Developer of immunomodulatory treatments for rare immunological diseases

hansabiopharma.com

Headquarters: Lund, Sweden
Founded year: 2007
Company type: Public company
Number of employees: 140–200
Industry: Pharmaceuticals

Last updated October 28

Latest news about Hansa Biopharma

In short: Hansa Biopharma filed an IND for HNSA-5487 and posted positive Idefirix PAES data at ASN Kidney Week.

Company announcements

October 28 Hansa Biopharma

Hansa Biopharma hosts Q3 2026 interim results conference call

The company releases its interim report for January to September 2026 on November 11. Management discusses financial results and pipeline updates during the English webcast.

October 14 Hansa Biopharma

Hansa Biopharma reports positive Idefirix PAES results

The study shows 90% graft failure-free survival at one year. Data presented at ASN Kidney Week supports continued use for highly sensitized patients.

August 21 Hansa Biopharma

Hansa Biopharma files draft SEC registration for potential US IPO

The company also plans a concurrent European private placement and intends to maintain its existing Nasdaq Stockholm listing while awaiting final regulatory approvals.

August 6 Hansa Biopharma

Hansa Biopharma carries out a directed new share issue in 2025

Press releases and appendices for the directed new share issue are available.

Media coverage

October 23 BioStock

Hansa on IND application for HNSA-5487 and selected PAES results

A license agreement worth 115 million euros allows Hansa Biopharma to focus fully on the US launch and the broader pipeline. The deal with SERB Pharmaceuticals, which...

September 17 GlobeNewswire

Anti-GBM Market Outlook to 2036: Evolving Epidemiology, Diagnostic Advances and Emerging Therapies Create New Growth Opportunities

Imlifidase represented an investigational approach designed to cleave immunoglobulin G antibodies rapidly. However, Hansa Biopharma discontinued the long-term follow-up phase of the Phase III GOOD-IDES-02...

August 24 BioStock

The biggest deals in Nordic life science 2026 - Biostock

Hansa Biopharma chose the opposite path and handed over development and commercialization rights for the transplant drug Idefirix in Europe and the MENA region when on May 19...

August 21 BioStock

News roundup Friday August 21 - Biostock

Hansa Biopharma announces that a confidential draft registration document has been submitted to the US SEC to enable a potential listing of American depositary receipts in...

Never miss news about Hansa Biopharma

Track Hansa Biopharma and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Hansa Biopharma competitors & trending companies

Browse news for competitors to Hansa Biopharma and other trending companies.